GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’13 Nov 2019
China-US trade challenges has led to de-risking by pharma companies.
GVK Bio, a global CRDO, has announced that a crescendo of market conditions and a strong customer pipeline are colliding to deliver strong growth in 2020.
During the past few years, the company has quickly consolidated its customer base in discovery and research services, with a subsequent positive impact on development services – which are now the fastest-growing part of the company.
Manni Kantipudi, Chief Executive Officer, added: “In the last year we have seen record revenues and teen figure growth for the company. But what is interesting is that whilst our research services – for which we are still best known – are growing at twice the market rate, it’s in development services that we are seeing growth running at three times the industry average.”
The company attributes its recent successes to robust regulatory standards and trust built up by pharma companies in the last few years – GVK Bio is now working with customers on some 18 compounds in commercial or late-stage development. Its discovery and development pipeline features more than 400 customers and over 60 molecules in various stages of clinical development.
“While we continue to benefit from our existing research services and our customers are increasingly staying with us now into development, we are also benefiting from wider macro market conditions, and seeing new customers approach us. Over the past year, there has been an influx of interest from Western life sciences firms, looking to diversify their discovery and development services outside of China to mitigate risk. This is in part due to trade tensions, but also due to tightening regulations and safety-related plant closures in China. The resulting disruption in the global supply chain, be it in discovery or development, has led to increasing interest in geographically diverse sourcing strategies, and GVK BIO, with its proven track record, has been a big beneficiary. So when you add this trend to the rise in outsourcing across pharma and the increasing virtualization of biotechs, we are bullish about our growth prospects through 2020 and beyond,” added Mr Kantipudi.
The company has also recently invested in expanding its biologics footprint in its San Francisco bio development subsidiary, Aragen Biosciences. Here, its newly commissioned suites support cell line development and GMP cell banking, in addition to existing capabilities across bioresearch.
“Our customers are always looking to reduce the time taken from discovery through to launch. By integrating our discovery and development efforts, GVK Bio is significantly reducing times for tech transfer, allowing our customers to expedite their clinical development efforts. Quality, delivery, and value are the three pillars around which we have built GVK BIO, with the sole purpose of accelerating our customer's R&D. We have no competing interests. This clear business model, and our success to date, continues to make us an attractive 'Partner of Choice' for both big pharma and biotechs worldwide.” concluded Mr Kantipudi.
Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment
4 Dec 2019
Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.Read more
Connectivity, customization and sustainability driving packaging and drug delivery in 2020
4 Dec 2019
Pharmapack 2020 gathering top specialists and pioneers to exchange their vision on best strategies to tackle key challenges.Read more
Eli Lilly unveils shared innovation laboratory in San Francisco
3 Dec 2019
Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.Read more
Ground-breaking work creates novel oil-in-water nanoemulsions
3 Dec 2019
New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.Read more
UK experiences a 'baby boom' of new life sciences ventures
2 Dec 2019
Unprecedented levels of investment cited as a major force driving the expansion.Read more
Pinpoint secures new investment to develop "ground-breaking" products
29 Nov 2019
The financial backing will help the company to develop a new generation of microbial air monitors that enables continuous monitoring as demanded by the Annex 1 revision.Read more
New single-use mixing system offers rapid and homogenous mixing
28 Nov 2019
ClearMixx performs liquid/liquid and powder/liquid mixing, with a dispersion plate able to efficiently mix the most challenging buffer, media and biopharmaceutical ingredients.Read more
Worldwide event predicts global pharma trends for 2020
27 Nov 2019
Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead.Read more
UK’s life sciences sector continues to attract talent despite Brexit fear
26 Nov 2019
The largest area of growth has been within biotechnology companies, where job openings increased by 35%.Read more
Dr Reddy’s enters Nutrition Segment with diabetes drink
25 Nov 2019
The company's diabetes nutrition drink, Celevida, is formulated to help manage blood glucose levels.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation